Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of pharmaceutical contractor Parexel
So what: Fiscal second-quarter results were decent with revenue rising to $364 million and net income increasing to $16.8 million, but investors were focused on the outlook for fiscal 2011. The company now expects earnings per share of $1.18 to $1.24, down from prior estimates of $1.23 to $1.31 per share.
Now what: Partnerships with Merck
Interested in more info on Parexel? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.